LMNL News and Press, Liminal Biosciences Inc From 03/25/21

Liminal BioSciences, Inc. (LMNL) Q4 2020 Earnings Conference Call March 25, 2021, 08:30 ET Company Participants Shrinal Inamdar - Investor Relations and Communications Manager Bruce Pritchard - CEO Patrick Sartore - President Murielle Lortie - CFO Conference Call Participants Yasmeen Rahimi -...

Liminal BioSciences (LMNL): FY Net loss of $122.1M.Revenue of $3.3M (-32.7% Y/Y) beats by $0.6M.Cash and cash equivalents at December 31, 2020 were $45.1 million. The Company's working capital, i.e., the current assets net of current liabilities, at December 31, 2020 amounted to $49.2 million...

Liminal BioSciences Reports Fourth Quarter and Year End 2020 Financial Results PR Newswire Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors &...

A new study has found that patients with COVID-19 given convalescent plasma did not show a survival benefit compared to those on standard of care.The study, which has yet to be peer reviewed, found that there was no difference in 28-day mortality between the two groups.Results also showed tha...

The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent d...

Cancer Genetics (CGIX) +131%.The OLB Group (OLB) +83% on plan to offer Cryptocurrency payment options via blockchain technology.BioHiTech Global (BHTG) +66%.Bio-Path Holdings (BPTH) +50%.Neptune Wellness Solutions (NEPT) +48% on acquisition of organic baby food maker Sprout Foods.Ga...